Protalix BioTherapeutics (PLX) Interest & Investment Income (2024 - 2026)
Protalix BioTherapeutics' quarterly Interest & Investment Income came in at $188000.0 in Q1 2026, down 55.13% year-on-year from $419000.0 in Q1 2025, and down 29.32% quarter-over-quarter from $266000.0 in Q4 2025.
Protalix BioTherapeutics has reported Interest & Investment Income for 3 years, with the latest figure at $188000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 55.13% year-over-year to $188000.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (down 23.91% YoY), and the FY2025 full-year result was $1.1 million, down 16.63% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $188000.0, down from $266000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $419000.0 in Q1 2025, with the low at $188000.0 in Q1 2026.
- Average Interest & Investment Income over 3 years is $293625.0, with a median of $280500.0 recorded in 2025.
- Year-over-year, Interest & Investment Income jumped 36.32% in 2025 and tumbled 55.13% in 2026.
- Tracing PLX's Interest & Investment Income over 3 years: stood at $329000.0 in 2024, then fell by 19.15% to $266000.0 in 2025, then slipped by 29.32% to $188000.0 in 2026.
- The last three Interest & Investment Income figures came in at $188000.0 (Q1 2026), $266000.0 (Q4 2025), and $289000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 266,000.00 |
| Sep 30, 2025 | 289,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 419,000.00 |
| Dec 31, 2024 | 329,000.00 |
| Sep 30, 2024 | 212,000.00 |
| Jun 30, 2024 | 374,000.00 |